The U.S. Food and Drug Administration (FDA) granted Onyx Pharmaceuticals' (Nasdaq:ONXX) Carfilzomib fast-track designation
Carfilzomib is the multiple-myeloma drug of Onyx Pharmaceuticals.
What this means is the review process will accelerate, and Onyx will be allowed to to submit its carfilzomib application on a rolling basis. With the fast-track, the company believes they could end the process by the middle of 2011. They already have the process in motion.
Onyx closed Monday at $35.28, gaining $0.78, or 2.25 percent.
No comments:
Post a Comment